<ul><li>Wall Street investors are investing tens of millions of dollars in psychedelic drugs that could treat mental illness for a fraction of the cost of traditional therapy.</li><li>Transcend Therapeutics, Gilgamesh Pharmaceuticals, and Lusaris Therapeutics have raised over $100 million since November to develop drugs for treating PTSD and depression.</li><li>The companies' focus on more cost-effective psychedelic therapy coincides with a selloff in biotech stocks last year that dampened enthusiasm for hallucinogens' commercial potential.</li></ul>

Wall Street bets millions on new class of psychedelic drugs

Discover more